Shukra Pharmaceuticals Ltd.
BSE: 524632 | Sector: Health care |
NSE: N.A. | ISIN Code: INE551C01028 |
BSE 00:00 | 07 Feb | 66.30 |
3.15 (4.99%) |
OPEN
66.30 |
HIGH
66.30 |
LOW
66.30 |
NSE 05:30 | 01 Jan | Shukra Pharmaceuticals Ltd |
OPEN | 66.30 |
PREVIOUS CLOSE | 63.15 |
VOLUME | 4557 |
52-Week high | 66.30 |
52-Week low | 11.14 |
P/E | 66.30 |
Mkt Cap.(Rs cr) | 73 |
Buy Price | 0.00 |
Buy Qty | 0.00 |
Sell Price | 0.00 |
Sell Qty | 0.00 |
Shukra Pharmaceuticals Ltd. (SHUKRAPHARMA) - Net Profit
Net Profit
COMPANY | LATEST(Rs) | CHG | CHG(%) | Net Profit (Rs crore) |
Cipla | 1031.35 | 1.60 | 0.16 | 2957.93 |
Divi's Lab. | 2749.20 | -28.95 | -1.04 | 2948.54 |
Glenmark Pharma. | 392.40 | -6.80 | -1.70 | 1997.79 |
Glaxosmi. Pharma | 1239.65 | 1.15 | 0.09 | 1690.53 |
Dr Reddy's Labs | 4441.90 | 91.85 | 2.11 | 1623.20 |
Alkem Lab | 3065.50 | -3.75 | -0.12 | 1541.25 |
Aurobindo Pharma | 418.65 | 3.20 | 0.77 | 1454.71 |
Gland Pharma | 1308.80 | 134.70 | 11.47 | 1212.16 |
Torrent Pharma. | 1535.05 | -4.75 | -0.31 | 991.45 |
Sanofi India | 5340.00 | 37.30 | 0.70 | 944.40 |
Ipca Labs. | 860.30 | 1.55 | 0.18 | 870.94 |
Zydus Lifesci. | 479.40 | 9.25 | 1.97 | 857.90 |
Abbott India | 20957.80 | 76.45 | 0.37 | 798.70 |
Laurus Labs | 330.30 | -3.80 | -1.14 | 750.09 |
Ajanta Pharma | 1187.70 | 23.65 | 2.03 | 719.86 |
Apollo Hospitals | 4317.85 | 0.60 | 0.01 | 665.20 |
Pfizer | 3868.45 | 3.05 | 0.08 | 612.56 |
Suven Pharma | 488.60 | -0.50 | -0.10 | 558.10 |
Alembic Pharma | 524.60 | -3.35 | -0.63 | 543.55 |
Glenmark Life | 377.40 | 2.20 | 0.59 | 418.72 |
Quick Links for Shukra Pharmaceuticals:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices